A​BL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and near-term payments [Press Release] SEONGNAM, South Korea, April 7, 2025 ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative d

PanGen contracts with Huonslab for biopharmaceutical process characterization study

[Press Release] On March 5, Huons Group PanGen (CEO Jaeseung Yoon) will conduct research services for Huonslab's biopharmaceutical product license. PanGen announced today that it has signed a research service contract with Huonslab for biopharmaceutical process characterization. The total value of the contract is KRW 800 million, and the process characterization research conducted through this contract is a service to design a standard process suitable for commercial-scale production of biopharm

Medytox signs botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica, from Brazil

Blau Farmacêutica S.A. (Brazil B3 BLAU3) will distribute Medytox’s products in the Brazilian market on an exclusive basis [Press Release] Medytox (CEO Hyun Ho Jung) announced on March 26th, 2024 that the biopharmaceutical company had entered into a distribution agreement (the "Agreement") with BLAU FARMACEUTICA S.A. (CEO Marcelo Hahn) for botulinum toxin at USD 73 million (based on minimum order quantity) for five years. Medytox will supply its botulinum toxin products (including Newlux) to Blau, which will distribute Medytox’s products in the territory of Brazil. The long-term Agreement came in the aftermath of Bl

Celltrion's STEQEYMA (ustekinumab-stba), now added to the Costco Member Prescription Program

Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program in August 2024 [Press Release] On March 27, Celltrion announced that STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab) has been added to the Costco Member Prescription Program. "We're focused on improving affordability and access to a widely used, high-cost treatment for a variety of inflammatory conditions," said Francine Galante, Vice President of Market Access at Celltrion USA. "The addition of STEQEYMA to the Costco Member Prescription Program together with adalimumab-aaty will help us del

Handok’s Collaborator, Compass Therapeutics, Announces Positive Topline Results from Phase 2/3 of Tovecimig (HDB001A)

Handok plans to use COMPANION-002 clinical results for domestic approval of tovecimig (HDB001A) [Press Release] Handok's collaborator, Compass Therapeutics, announced positive topline results of COMPANION-002, a Phase 2/3 trial of tovecimig (HDB001A) in patients with metastatic or recurrent biliary tract cancer on April 1st (U.S. time). Handok and Compass Therapeutics have been collaborating on the development of tovecimig (HDB001A), an innovative bispecific antibody drug with high potential as a biliary tract cancer treatment. Compass Therapeutics has conducted the Phase 2/3 trial, COMPAN

ST PHARM Participates in DCAT Week 2025, Seeking Global Partnerships

Continuing participation following last year, aiming to attract global clients [Press Release] ST PHARM announced on March 21st that it participated in the Drug, Chemical & Associated Technologies (DCAT) Week 2025, held in New York City from March 17th to 20th. DCAT Week, which began in 1890 under the auspices of the New York Chamber of Commerce, is a premier event in the pharmaceutical and biotech sectors with over 150 years of tradition. The event is well-known for providing various forms of B2B partnering meetings, especially as it attracts high-level executives with de

Bioneer Participates in the American Academy of Dermatology (AAD)

Launches 'Cosmerna' Marketing in the North American Market [Press Release] Bioneer announced on the 12th that it participated for the first time in the American Academy of Dermatology (AAD) held in Orlando, Florida, USA, from March 7th to 11th. The company set up a booth for its hair loss cosmetic product "CosmeRNA" and conducted marketing activities for the brand during the event. The American Academy of Dermatology (AAD), established in 1939, is a globally renowned dermatology association with over 20,000 members from more than 100 countries, includin

SK bioscience and IVI Announce the 2025 Recipients of the ‘Park MahnHoon Award’ Four Honorees Recognized

Recipients selected for achievements in polio vaccine development and nonprofit initiatives to improve vaccination rates [Press Release] SK bioscience and the International Vaccine Institute (IVI) today announced the recipients of the 2025 Park MahnHoon Award, widely regarded as the "Nobel Prize of the vaccine industry." The honorees are Professor Pierre van Damme of the University of Antwerp and Dr. Ananda Sankar Bandyopadhyay of the Gates Foundation (joint recipients), as well as Ms. Luiza Helena Trajano, Chair of Grupo Mulheres do Brasil, and Ms. Svetha Janumpalli, CEO and Co-Founder of New Incentives (joint re

Medytox signs botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica, from Brazil

Blau Farmacêutica S.A. (Brazil B3 BLAU3) will distribute Medytox’s products in the Brazilian market on an exclusive basis [Press Release] Medytox (CEO Hyun Ho Jung) announced on March 26th, 2024 that the biopharmaceutical company had entered into a distribution agreement (the "Agreement") with BLAU FARMACEUTICA S.A. (CEO Marcelo Hahn) for botulinum toxin at USD 73 million (based on minimum order quantity) for five years. Medytox will supply its botulinum toxin products (including Newlux) to Blau, which will distribute Medytox’s products in the territory of Brazil. The long-term Agreement came in the aftermath of Bl

Samsung Biologics recognized for leadership band in water security

[Press Release] Samsung Biologics announced on February 12 that it has received 'Leadership' status and an A- rating for water security from the Carbon Disclosures Project (CDP), underscoring the company’s efficient water resources management. The company participated in the category for the first time. CDP is a non-profit organization that evaluates the corporate environmental transparency and performance of over 24,800 companies listed worldwide. The rating recognizes Samsung Biologics’ effort